| SHL Designs New Pen Injector Device for Precise Drug Dose Delivery | ||||
|
|
Issued by: BiotechEast Issued on: 2009/02/04 (BiotechEast staff) 4 February, 2009 Scandinavian Health Ltd. (SHL), a designer and manufacturer of medical devices, announced today that it had designed a new Precision Pen Injector (PPI) device that can deliver small but highly accurate drug doses. The Taoyuan, Taiwan-headquartered company also announced that the device would be used by Swedish biomedical company Q-Med AB to deliver Restylane Vital™ Light, its treatment for rejuvenating delicate skin. According to SHL, the device replaces traditional syringes where accuracy can be difficult to control, with the new PPI enabling users to quickly and precisely deliver 200 doses of 10μl with an accuracy far exceeding the requirements of pen-injector standards. Over the years SHL had developed a number of pipeline products ready to be customized for specific projects, and it was one of these products that provided the platform for the PPI, enabling the company to quickly develop a solution for Q-Med, according to the announcement. "We are excited about the launch of this new device. The PPI is innovative and is an example of how teamwork can overcome design and development challenges. Our customer has worked closely with us from the very beginning, with SHL staff from Sweden and Taiwan partnering up to get this unique device to market," commented Steven R. Kaufman, marketing director at SHL. SHL Group consists of three companies: SHL Medical, SHL Healthcare and SHL Technologies. SHL Medical develops high-end drug delivery devices, SHL Healthcare produces rehabilitation equipment for home and hospital markets, and SHL Technologies makes med-tech and other industrial products. The group has manufacturing facilities in Taiwan and China, design centers in Sweden, Taiwan and the USA, and employsover 1,500 worldwide. Original Article: About SHL SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,500 staff globally (1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities. Our organization consists of three distinct group companies:
SHL Medical SHL Healthcare SHL Technologies For additional information visit www.shl-group.com or contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it SHL Media ContactSteven R. Kaufman Marketing Director +886 932 111 460 This e-mail address is being protected from spambots. You need JavaScript enabled to view it |